Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BioAge Labs, Inc. ( (BIOA) ) has issued an update.
On January 20, 2026, BioAge Labs announced an expansion of its BGE-102 development program into ophthalmology, unveiling plans to launch a Phase 1b/2a proof-of-concept clinical trial in patients with diabetic macular edema (DME) in mid-2026, with data expected in mid-2027. BGE-102, an oral NLRP3 inhibitor that has shown favorable safety and robust biomarker reductions in an ongoing Phase 1 trial for cardiovascular risk, is supported by preclinical DME data demonstrating near-complete protection from retinal vascular leakage and substantial preservation of microvascular integrity. The DME study will assess BGE-102 as monotherapy and in combination with VEGF inhibitors, focusing on intraocular IL-6 and visual and anatomical endpoints, and will run in parallel with a Phase 2a cardiovascular risk trial slated to read out in the second half of 2026, positioning BGE-102 as a potential multi-indication, inflammation-targeting asset across cardiovascular and retinal diseases.
The most recent analyst rating on (BIOA) stock is a Hold with a $21.50 price target. To see the full list of analyst forecasts on BioAge Labs, Inc. stock, see the BIOA Stock Forecast page.
Spark’s Take on BIOA Stock
According to Spark, TipRanks’ AI Analyst, BIOA is a Neutral.
The score is held back primarily by weak financial performance (large losses and significant cash burn despite low leverage). Offsetting this, technicals are strong with a clear uptrend and positive momentum, and recent clinical/patent news provides meaningful positive catalysts. Valuation remains constrained by lack of profitability and no dividend support.
To see Spark’s full report on BIOA stock, click here.
More about BioAge Labs, Inc.
BioAge Labs, Inc., based in Emeryville, California, is a clinical-stage biopharmaceutical company focused on developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. Its lead asset, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed primarily for elevated cardiovascular risk and retinal diseases, while additional pipeline programs include long-acting injectable and oral APJ agonists for obesity and other preclinical assets leveraging a proprietary human longevity data platform.
Average Trading Volume: 621,377
Technical Sentiment Signal: Buy
Current Market Cap: $722.8M
See more insights into BIOA stock on TipRanks’ Stock Analysis page.